STAB (Statera BioPharma) Cyclically Adjusted Revenue per Share: $ (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma Cyclically Adjusted Revenue per Share?

Statera BioPharma STAB -50.00% Cyclically Adjusted Revenue per Share is $ as of Sep. 2022.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Statera BioPharma's adjusted revenue per share for the three months ended in Sep. 2022 was $0.013. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $ for the trailing ten years ended in Sep. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-09-21), Statera BioPharma's current stock price is $0.0001. Statera BioPharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2022 was $. Statera BioPharma's Cyclically Adjusted PS Ratio of today is .


Statera BioPharma  (OTCPK:STAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Statera BioPharma Cyclically Adjusted Revenue per Share Related Terms


Statera BioPharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Cyclically Adjusted Revenue per Share Chart

Statera BioPharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Statera BioPharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STAB vs NRBO, PALI, BLCM: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Statera BioPharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Cyclically Adjusted PS Ratio falls into.



Statera BioPharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Statera BioPharma's adjusted Revenue per Share data for the three months ended in Sep. 2022 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.013/296.8080*296.8080
=0.013

Current CPI (Sep. 2022) = 296.8080.

Statera BioPharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 1.016 229.601 1.313
201303 0.610 232.773 0.778
201306 0.718 233.504 0.913
201309 0.726 234.149 0.920
201312 1.714 233.049 2.183
201403 0.534 236.293 0.671
201406 0.217 238.343 0.270
201409 0.145 238.031 0.181
201412 0.487 234.812 0.616
201503 0.189 236.119 0.238
201506 0.083 238.638 0.103
201509 0.049 237.945 0.061
201512 0.118 236.525 0.148
201603 0.074 238.132 0.092
201606 0.052 241.018 0.064
201609 0.104 241.428 0.128
201612 0.090 241.432 0.111
201703 0.052 243.801 0.063
201706 0.018 244.955 0.022
201709 0.026 246.819 0.031
201712 0.077 246.524 0.093
201803 0.020 249.554 0.024
201806 0.035 251.989 0.041
201809 0.025 252.439 0.029
201812 0.021 251.233 0.025
201903 0.018 254.202 0.021
201906 0.025 256.143 0.029
201909 0.024 256.759 0.028
201912 0.033 256.974 0.038
202003 0.014 258.115 0.016
202006 0.005 257.797 0.006
202009 0.000 260.280 0.000
202012 0.000 260.474 0.000
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.009 274.310 0.010
202112 0.035 278.802 0.037
202203 0.026 287.504 0.027
202206 0.015 296.311 0.015
202209 0.013 296.808 0.013

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $ mean?
Statera BioPharma (STAB) has a Cyclically Adjusted Revenue per Share of $ as of Sep. 2022. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Cyclically Adjusted Revenue per Share too high?
Statera BioPharma's current Cyclically Adjusted Revenue per Share is $.
How does Statera BioPharma's Cyclically Adjusted Revenue per Share compare to NRBO and PALI?
Statera BioPharma's Cyclically Adjusted Revenue per Share of $ can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Cyclically Adjusted Revenue per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STAB) has a current Cyclically Adjusted Revenue per Share of $. The current Cyclically Adjusted Revenue per Share is $. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Statera BioPharma (STAB), the current Cyclically Adjusted Revenue per Share is $ as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.